Wright Bonilla Quoted on NIH March-In Rights

16 August 2010 BioWorld Insight News
Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BioWorld Insight on August 16, 2010 titled "If NIH Challenges Genzyme’s Patents, Does Anyone Care?" Wright Bonilla discusses a petition filed with the Department of Health and Human Services urging the National Institutes of Health (NIH) to exercises its march-in rights and grant an open license for the use of patents related to Genzyme Corp.’s Fabry disease drug Fabrazyme. She states that it is unlikely that the NIH would pursue an open license for Genzyme’s product because of the complexity of making biologics like Fabrazyme, adding that the agency has in fact never before exercised its march-in rights.

Related Services

Insights

Review of Recent Whistleblower Developments
30 July 2021
Legal News: Whistleblower Developments
$4.24M Now the Average Cost Per Data Breach!
30 July 2021
Internet, IT & e-Discovery Blog
Podcast Episode 56: All Things Summer Associate Recruiting
30 July 2021
Foley Career Perspectives
Foley Podcast to Live Panel Discussion
29 July 2021
Foley Career Perspectives
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream